Patents Assigned to Genentech
  • Publication number: 20160175435
    Abstract: The present invention concerns treatment of pemphigus with an antibody which binds to CD20.
    Type: Application
    Filed: July 16, 2015
    Publication date: June 23, 2016
    Applicants: BIOGEN INC., GENENTECH, INC.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez
  • Publication number: 20160175284
    Abstract: Described herein are compounds that are estrogen receptor modulators of Formula I: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Application
    Filed: December 17, 2015
    Publication date: June 23, 2016
    Applicant: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Li, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Steven P. Govek, Mehmet Kahraman, Johnny Y. Nagasawa, Nicholas D. Smith
  • Publication number: 20160175438
    Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; and treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag.
    Type: Application
    Filed: March 2, 2016
    Publication date: June 23, 2016
    Applicant: Genentech, Inc.
    Inventors: Sreedhara Alavattam, Lukas C. Amler, Mark C. Benyunes, Emma L. Clark, Christina H. de Toledo Pelizon, Zephania W. Kwong Glover, Lada Mitchell, Jayantha Ratnayake, Graham A. Ross, Ru-Amir Walker
  • Publication number: 20160168261
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of detecting or determining the presence of STEAP-1 proteins are provided.
    Type: Application
    Filed: November 30, 2015
    Publication date: June 16, 2016
    Applicant: Genentech, Inc.
    Inventors: Mark DENNIS, Jan MARIK, Paul POLAKIS, Bonnee RUBINFELD, Simon WILLIAMS
  • Publication number: 20160168234
    Abstract: The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease.
    Type: Application
    Filed: July 20, 2015
    Publication date: June 16, 2016
    Applicants: GENENTECH, INC., AC IMMUNE S.A.
    Inventors: Andrea Pfeifer, Maria Pihlgren, Andreas Muhs, Ryan Watts
  • Publication number: 20160166689
    Abstract: The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. ?,?-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.
    Type: Application
    Filed: February 25, 2016
    Publication date: June 16, 2016
    Applicant: Genentech, Inc.
    Inventors: Michael Adler, Ulla Grauschopf, Hanns-Christian Mahler, Oliver Boris Stauch
  • Publication number: 20160168141
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, W, X1, X2, X3, X4, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 16, 2016
    Applicant: Genentech, Inc.
    Inventors: Benjamin Fauber, Alberto Gobbi, Olivier Rene, Monique Bodil van Niel, Emanuela Gancia, Simon Gaines, Tammy Ladduwahetty, David Vesey, Stuart Ward, Paul Winship
  • Publication number: 20160166685
    Abstract: The invention provides compositions and methods for treating cancers. The method comprises administering a PD-1 axis binding antagonist and an OX40 binding agonist.
    Type: Application
    Filed: November 16, 2015
    Publication date: June 16, 2016
    Applicant: GENENTECH, INC.
    Inventors: Jeanne CHEUNG, Mahrukh HUSENI, Jeong KIM
  • Publication number: 20160168230
    Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
    Type: Application
    Filed: February 12, 2016
    Publication date: June 16, 2016
    Applicant: Genentech, Inc.
    Inventors: Min XU, Mercedesz BALAZS, Ning CHA, Nancy CHIANG, Henry CHIU, Zhaoyu JIN, Zhonghua LIN, Patrick LUPARDUS, Gerald R. NAKAMURA, Hyunjoo PARK, Lee SWEM
  • Patent number: 9365583
    Abstract: The present invention provides for compounds of formula 0 and various embodiments thereof, and compositions comprising compounds of formula 0 and various embodiments thereof. In compounds of formula 0, the groups R1A, R1B, R1C, R1D, R2, R3, R4, R5 and R6 have the meaning as described herein. The present invention also provides for methods of using compounds of formula 0 and compositions comprising compounds of formula 0 as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: June 14, 2016
    Assignee: Genentech, Inc.
    Inventors: Michael Siu, Anthony Estrada, Wen Liu, Joseph P. Lyssikatos, Snahel Patel, Guibai Liang, Kevin Chen
  • Patent number: 9365642
    Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: June 14, 2016
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Marissa L. Matsumoto
  • Publication number: 20160159797
    Abstract: Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: February 16, 2016
    Publication date: June 9, 2016
    Applicant: Genentech, Inc.
    Inventors: Steven Do, Huiyong Hu, Aleksandr Kolesnikov, Wendy Lee, Vickie Hsiao-Wei Tsui, Xiaojing Wang, Zhaoyang Wen
  • Publication number: 20160160213
    Abstract: Provided herein are methods of treating and/or preventing cancer drug resistance using modulators of chromatin modifiers (e.g., antagonists of chromatin modifiers) described herein.
    Type: Application
    Filed: September 14, 2015
    Publication date: June 9, 2016
    Applicant: GENENTECH, INC.
    Inventors: Marie Classon, Jean-Philippe Stephan
  • Publication number: 20160160290
    Abstract: The present disclosure provides methods for predicting responsiveness of a subject having cancer to an OX40 agonist treatment by measuring the expression level of one or more biomarkers. Also provided are methods for monitoring pharmacodynamic activity of or responsiveness to an OX40 agonist treatment by measuring the expression level of one or more biomarkers. Further provided are methods related thereto for treating or delaying progression of cancer in a subject by administering an effective amount of an OX40 agonist to a subject. Specific biomarkers for all such methods are described herein.
    Type: Application
    Filed: November 2, 2015
    Publication date: June 9, 2016
    Applicant: GENENTECH, INC.
    Inventor: Mahrukh HUSENI
  • Publication number: 20160158207
    Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Application
    Filed: November 25, 2015
    Publication date: June 9, 2016
    Applicants: Genentech, Inc., Constellation Pharmaceuticals, Inc.
    Inventors: Marc Adler, Brian K. Albrecht, Sarah Bronner, Kevin X. Chen, Alexandre Côté, Terry Crawford, Patrick Cyr, Jackson Egen, Steven Kauder, Kwong Wah Lai, Jiangpeng Liao, Steven Magnuson, Jeremy Murray, Richard Pastor, F. Anthony Romero, Alexander M. Taylor, Vickie Hsiao-Wei Tsui, Fei Wang, Bing-Yan Zhu
  • Publication number: 20160159906
    Abstract: The invention provides anti-CD79b antibodies and methods of using the same.
    Type: Application
    Filed: December 4, 2015
    Publication date: June 9, 2016
    Applicant: Genentech, Inc.
    Inventors: Liping L. Sun, Yvonne Man-Yee Chen, Mark S. Dennis, Allen J. Ebens, JR., Andrew Polson
  • Publication number: 20160159898
    Abstract: Provided herein are methods of producing a polypeptide containing two chains, such as an antibody including a light chain and a heavy chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes.
    Type: Application
    Filed: November 5, 2015
    Publication date: June 9, 2016
    Applicant: GENENTECH, INC.
    Inventors: James GIULIANOTTI, Dorothea REILLY
  • Publication number: 20160159910
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: September 11, 2015
    Publication date: June 9, 2016
    Applicant: GENENTECH, INC.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • Publication number: 20160159880
    Abstract: Provided herein are methods of producing a recombinant polypeptide containing two chains, such as an immune mobilizing monoclonal T-cell receptor against cancer (ImmTAC) protein including an alpha chain and a beta chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes.
    Type: Application
    Filed: November 5, 2015
    Publication date: June 9, 2016
    Applicant: GENENTECH, INC.
    Inventors: James GIULIANOTTI, Dorothea REILLY, Kieran Aurori, Laura C. Simmons
  • Publication number: 20160158234
    Abstract: The present invention provides for compounds of Formula I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula all have the meaning as defined herein.
    Type: Application
    Filed: February 11, 2016
    Publication date: June 9, 2016
    Applicant: Genentech, Inc.
    Inventors: Anthony O. Estrada, Alan G Olivero, Snahel Patel, Michael Siu